» Articles » PMID: 1969451

Induction of Proliferation of Human Follicular (B Type) Lymphoma Cells by Cognate Interaction with CD4+ T Cell Clones

Overview
Journal J Immunol
Date 1990 Apr 1
PMID 1969451
Citations 26
Authors
Affiliations
Soon will be listed here.
Abstract

We examined stimuli which are required for the induction of in vitro proliferation of follicular lymphoma cells, a low grade non-Hodgkin's B cell lymphoma characterized by a specific chromosomal translocation, t(14;18)(q32;q21), and by in vivo growth of the lymphoma cells in germinal center-like follicles infiltrated with CD4+ T cells. The purified follicular lymphoma cells, which are morphologically uniform, small, and dense, did not respond to stimulation with soluble lymphokines in the absence of T cells. Vigorous in vitro proliferation of follicular lymphoma cells was induced, however, when the follicular lymphoma cells were cultured with a CD4+ T cell clone which recognized alloantigens expressed by the lymphoma cells. This response required B-T cell contact, and was inhibited by anti-class II but not by anti-class I MHC mAb, indicating that these neoplastic B cells behaved as normal B cells and responded to normal activation and differentiation signals from T cells. After the cognate B lymphoma-T cell interaction occurred in culture, addition of IL-2 or IL-4 enhanced the proliferation of the tumor cells. These results, with a monoclonal and homogeneous population of B cells, affirm the idea that cognate interaction between B cells and Th cells is required for the effective activation of resting B cells. Moreover, these results suggest that a critical host-tumor interaction occurs in vivo, and that the polyclonal CD4+ T cells that infiltrate follicular lymphomas play a role in sustaining rather than inhibiting tumor growth in vivo. If so, therapies directed not only against the neoplastic cell but also against specific T cells and their cognate interactions with tumor cells may have a rationale.

Citing Articles

B Cell Differentiation and the Origin and Pathogenesis of Human B Cell Lymphomas.

Weniger M, Seifert M, Kuppers R Methods Mol Biol. 2024; 2865:1-30.

PMID: 39424718 DOI: 10.1007/978-1-0716-4188-0_1.


A human lymphoma organoid model for evaluating and targeting the follicular lymphoma tumor immune microenvironment.

Kastenschmidt J, Schroers-Martin J, Sworder B, Sureshchandra S, Khodadoust M, Liu C Cell Stem Cell. 2024; 31(3):410-420.e4.

PMID: 38402619 PMC: 10960522. DOI: 10.1016/j.stem.2024.01.012.


Tumor Microenvironment and Microvascular Density in Follicular Lymphoma.

Tamma R, Ingravallo G, Annese T, Gaudio F, Perrone T, Musto P J Clin Med. 2022; 11(5).

PMID: 35268349 PMC: 8911525. DOI: 10.3390/jcm11051257.


Follicular lymphoma and macrophages: impact of approved and novel therapies.

Gouni S, Marques-Piubelli M, Strati P Blood Adv. 2021; 5(20):4303-4312.

PMID: 34570196 PMC: 8945644. DOI: 10.1182/bloodadvances.2021005722.


Heat Shock Proteins in Lymphoma Immunotherapy.

Albakova Z, Mangasarova Y, Sapozhnikov A Front Immunol. 2021; 12:660085.

PMID: 33815422 PMC: 8012763. DOI: 10.3389/fimmu.2021.660085.